Tumour treating fields therapy for glioblastoma: current advances and future directions

Glioblastoma multiforme (GBM) is the most common primary brain tumour in adults and continues to portend poor survival, despite multimodal treatment using surgery and chemoradiotherapy. The addition of tumour-treating fields (TTFields)—an approach in which alternating electrical fields exert biophys...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer Vol. 124; no. 4; pp. 697 - 709
Main Authors: Rominiyi, Ola, Vanderlinden, Aurelie, Clenton, Susan Jane, Bridgewater, Caroline, Al-Tamimi, Yahia, Collis, Spencer James
Format: Journal Article
Language:English
Published: London Nature Publishing Group UK 16.02.2021
Nature Publishing Group
Subjects:
631/67/1922
639/766
692/4028/67/1059/485
692/4028/67/1059/602
692/4028/67/1059/99
Animals
Biomedical and Life Sciences
Biomedicine
Brain cancer
Brain Neoplasms - pathology
Brain Neoplasms - therapy
Brain tumors
Cancer
Cancer Research
Cell permeability
Cell proliferation
Chemoradiotherapy
Chemotherapy
Clinical trials
Clinical Trials, Phase III as Topic
DNA repair
Drug Resistance
Electric fields
Electric Stimulation Therapy - methods
Epidemiology
Glioblastoma
Glioblastoma - pathology
Glioblastoma - therapy
Humans
Mesothelioma
Molecular Medicine
Oncology
Radiation therapy
Randomized Controlled Trials as Topic
Review
Review Article
Surgery
ISSN:0007-0920, 1532-1827, 1532-1827
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Glioblastoma multiforme (GBM) is the most common primary brain tumour in adults and continues to portend poor survival, despite multimodal treatment using surgery and chemoradiotherapy. The addition of tumour-treating fields (TTFields)—an approach in which alternating electrical fields exert biophysical force on charged and polarisable molecules known as dipoles—to standard therapy, has been shown to extend survival for patients with newly diagnosed GBM, recurrent GBM and mesothelioma, leading to the clinical approval of this approach by the FDA. TTFields represent a non-invasive anticancer modality consisting of low-intensity (1–3 V/cm), intermediate-frequency (100–300 kHz), alternating electric fields delivered via cutaneous transducer arrays configured to provide optimal tumour-site coverage. Although TTFields were initially demonstrated to inhibit cancer cell proliferation by interfering with mitotic apparatus, it is becoming increasingly clear that TTFields show a broad mechanism of action by disrupting a multitude of biological processes, including DNA repair, cell permeability and immunological responses, to elicit therapeutic effects. This review describes advances in our current understanding of the mechanisms by which TTFields mediate anticancer effects. Additionally, we summarise the landscape of TTFields clinical trials across various cancers and consider how emerging preclinical data might inform future clinical applications for TTFields.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:0007-0920
1532-1827
1532-1827
DOI:10.1038/s41416-020-01136-5